It can form NPM-ALK fusions in ~60% of anaplastic large-cell lymphomas (ALCLs)50, or EML-ALK in a subset of non-small-cell lung cancers51; additionally, it can have gain-of-function point mutations in neuroblastomas52, and copy number gain in several tumor types53. This evidence concerns the gene ALK and neoplasm.